Seres receives $125M payment from Nestlé; French biotech teases early-stage eye disease data
Seres Therapeutics, a microbiome-focused biotech, has been handed a $125 million milestone payment from Nestlé Heath Science related to the FDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
